Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Among other approaches, the modulation of the dopaminergic pathway has been advocated in the therapeutic management of Alcohol Use Disorders (AUD). A potential avenue toward the modulation of the dopaminergic pathway across varying substance disorders seems to be provided by aripiprazole, a second-generation antipsychotic characterized by a peculiar pharmacodynamics signature. AREAS COVERED: In this review, the authors provided a qualitative synthesis and a critical perspective on the efficacy of aripiprazole in relapse prevention and craving in AUD. A systematic search was carried out through MEDLINE/Embase/PsycINFO/Cochrane Library from inception until September 2015, combining free terms and MESH headings for the topics of AUD and aripiprazole as following: (((Alcohol use Disorder) OR (Alcohol use)) AND aripiprazole). EXPERT OPINION: Based both on a qualitative synthesis and a critical interpretation of the evidence, the authors submit that aripiprazole would promote alcohol abstinence and reduce the alcohol seeking behaviour possibly via dopaminergic and serotoninergic modulations at the fronto-subcortical circuits underpinning alcohol reward and craving, impulsive behaviour as well as reduce alcohol-related anxiety/low mood and anhedonia. However, due to the lack of published studies, a conclusive statement about any direct effect of aripiprazole in the prevention of craving and/or alcohol consumption is not possible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The incentive sensitization theory of addiction: some current issues
Robinson, T. E., & Berridge, K. C. (2008) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2008.0093 · Cited by 1,717 · cited 1×
“tional (or drug ‘wanting’) subcomponent of the reward.[4,5]”
BackgroundIs there a common molecular pathway for addiction?
Nestler, E. J. (2005) · Nature Neuroscience · doi:10.1038/nn1578 · Cited by 1,388 · cited 1×
“[1] Heterogeneous mechanisms of action invol-”
Affective neuroscience of pleasure: reward in humans and animals
Berridge, K. C., & Kringelbach, M. L. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1099-6 · Cited by 1,254
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Plasticity of reward neurocircuitry and the ‘dark side’ of drug addiction
Koob, G. F., & Le Moal, M. (2005) · Nature Neuroscience · doi:10.1038/nn1105-1442 · Cited by 963 · cited 1×
“[8,46] On the other hand, relapse drinking or initiation has been associated with increased dopamine concentrations at the striatum.[49,50] Therefore, all drugs acting in the modulation of the dopaminergic system may theoretically reduce craving and prevent relapse, by promoting abstinence, in alcohol-dependent patien…”
BackgroundDrug addiction: the neurobiology of disrupted self-control
Baler, R. D., & Volkow, N. D. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.10.005 · Cited by 640 · cited 1×
“[8,46] On the other hand, relapse drinking or initiation has been associated with increased dopamine concentrations at the striatum.[49,50] Therefore, all drugs acting in the modulation of the dopaminergic system may theoretically reduce craving and prevent relapse, by promoting abstinence, in alcohol-dependent patien…”
BackgroundAlcohol dependence is associated with blunted dopamine transmission in the ventral striatum
Martinez, D., Gil, R., Slifstein, M., Hwang, D.-R., Huang, Y., Perez, A., Kegeles, L., Talbot, P., Evans, S., Krystal, J., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.044 · Cited by 445
Heinz, A., Siessmeier, T., Wrase, J., Buchholz, H. G., Gründer, G., Kumakura, Y., Cumming, P., Schreckenberger, M., Smolka, M. N., Rösch, F., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1515 · Cited by 285
Development of pharmacotherapies for drug addiction: a Rosetta stone approach
Koob, G. F., Kenneth Lloyd, G., & Mason, B. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2828 · Cited by 154
Cited by
Martinotti, G., Santacroce, R., Pettorruso, M., Montemitro, C., Spano, M., Lorusso, M., Di Giannantonio, M., & Lerner, A. (2018) · Brain Sciences · doi:10.3390/brainsci8030047 · Cited by 171
Self-citationAddiction, Anhedonia, and Comorbid Mood Disorder. A Narrative Review
Destoop, M., Morrens, M., Coppens, V., & Dom, G. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00311 · Cited by 85
Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review
Fischler, P. V., Soyka, M., Seifritz, E., & Mutschler, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927703 · Cited by 34
“In a review of aripiprazole in the treatment of alcohol use disorder, it was not only found to be effective for promoting alcohol abstinence, but also performed well in the reduction of craving, improved control of impulsive behavior and reduced alcohol-related psychic symptoms and anxiety (Martinotti et al., 2016).”
BackgroundSkryabin, V. Y., Vinnikova, M. A., Ezhkova, E. V., Titkov, M. S., & Bulatova, R. A. (2021) · Journal of Addictive Diseases · doi:10.1080/10550887.2021.1905589 · Cited by 17
Metadata
- Authors
- Martinotti, G., Orsolini, L., Fornaro, M., Vecchiotti, R., De Berardis, D., Iasevoli, F., Torrens, M., & Di Giannantonio, M.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2016-04-21
- Volume
- 25
- Issue
- 6
- Pages
- 719-728
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2339758256
- Cited by
- 42
- References
- 9
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. https://app.cochat.ai/papers/10.1080/13543784.2016.1175431
- The paper
- Martinotti, G., Orsolini, L., Fornaro, M., Vecchiotti, R., De Berardis, D., Iasevoli, F., Torrens, M., & Di Giannantonio, M. (2016). Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2016.1175431
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.